Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Tonix Pharmaceuticals Holding stock | $0.815

Own Tonix Pharmaceuticals Holding stock in just a few minutes.

Fact checked

Tonix Pharmaceuticals Holding Corp is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Tonix Pharmaceuticals Holding employs 16 staff and has a market cap (total outstanding shares value) of USD$241.5 million.

How to buy shares in Tonix Pharmaceuticals Holding

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Tonix Pharmaceuticals Holding. Find the stock by name or ticker symbol: TNXP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Tonix Pharmaceuticals Holding reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.815, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Tonix Pharmaceuticals Holding, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Tonix Pharmaceuticals Holding. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Tonix Pharmaceuticals Holding share price

Use our graph to track the performance of TNXP stocks over time.

Tonix Pharmaceuticals Holding shares at a glance

Information last updated 2021-01-19.
Latest market closeUSD$0.815
52-week rangeUSD$0.3902 - USD$1.98
50-day moving average USD$0.6976
200-day moving average USD$0.8017
Wall St. target priceUSD$3.25
PE ratio 0.1372
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-8.251

Buy Tonix Pharmaceuticals Holding shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Tonix Pharmaceuticals Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tonix Pharmaceuticals Holding price performance over time

Historical closes compared with the close of $0.815 from 2021-01-11

1 week (2021-01-12) N/A
1 month (2020-12-19) N/A
3 months (2020-10-19) N/A
6 months (2020-07-19) N/A
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Is Tonix Pharmaceuticals Holding under- or over-valued?

Valuing Tonix Pharmaceuticals Holding stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tonix Pharmaceuticals Holding's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Tonix Pharmaceuticals Holding's P/E ratio

Tonix Pharmaceuticals Holding's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Tonix Pharmaceuticals Holding shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Tonix Pharmaceuticals Holding financials

Gross profit TTM USD$0
Return on assets TTM -66.06%
Return on equity TTM -116.4%
Profit margin 0%
Book value $0.446
Market capitalisation USD$241.5 million

TTM: trailing 12 months

Shorting Tonix Pharmaceuticals Holding shares

There are currently 2.8 million Tonix Pharmaceuticals Holding shares held short by investors – that's known as Tonix Pharmaceuticals Holding's "short interest". This figure is 388.6% up from 573,236 last month.

There are a few different ways that this level of interest in shorting Tonix Pharmaceuticals Holding shares can be evaluated.

Tonix Pharmaceuticals Holding's "short interest ratio" (SIR)

Tonix Pharmaceuticals Holding's "short interest ratio" (SIR) is the quantity of Tonix Pharmaceuticals Holding shares currently shorted divided by the average quantity of Tonix Pharmaceuticals Holding shares traded daily (recently around 21.5 million). Tonix Pharmaceuticals Holding's SIR currently stands at 0.13. In other words for every 100,000 Tonix Pharmaceuticals Holding shares traded daily on the market, roughly 130 shares are currently held short.

However Tonix Pharmaceuticals Holding's short interest can also be evaluated against the total number of Tonix Pharmaceuticals Holding shares, or, against the total number of tradable Tonix Pharmaceuticals Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tonix Pharmaceuticals Holding's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Tonix Pharmaceuticals Holding shares in existence, roughly 10 shares are currently held short) or 0.0146% of the tradable shares (for every 100,000 tradable Tonix Pharmaceuticals Holding shares, roughly 15 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tonix Pharmaceuticals Holding.

Find out more about how you can short Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding share dividends

We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.

Have Tonix Pharmaceuticals Holding's shares ever split?

Tonix Pharmaceuticals Holding's shares were split on a 1:10 basis on 1 November 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.

Tonix Pharmaceuticals Holding share price volatility

Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $0.3902 up to $1.98. A popular way to gauge a stock's volatility is its "beta".

TNXP.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 1.5804. This would suggest that Tonix Pharmaceuticals Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Tonix Pharmaceuticals Holding overview

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) portfolio comprises small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300, a second live replicating vaccine candidate for the prevention of COVID-19 that employs bovin parainfluenza virus as the vector. In addition, the company's lead CNS candidate is TNX-102 SL, which is in Phase 3 development for fibromyalgia, as well as in Phase 2 studies for agitation in Alzheimer's disease and alcohol use disorder. Further, its products include TNX-1300, which is in Phase 2 development for the treatment of life-threatening cocaine intoxication; TNX-601 CR (tianeptine oxalate controlled-release tablets) that is in Phase 1 development for depression; and TNX-1900, an intranasal oxytocin as a non-addictive treatment for migraine and cranio-facial pain. Additionally, its preclinical pipeline includes TNX-1600, a triple reuptake inhibitor for posttraumatic stress disorder; TNX-1500, a monoclonal antibody to prevent and treat organ transplant rejection and autoimmune conditions; and TNX 1700, a recombinant modified form of Trefoil Family Factor 2 to treat gastric and pancreatic cancers. It has a research collaboration agreement with Massachusetts General Hospital to develop TNX-1500. The company was founded in 2007 and is based in New York, New York.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site